Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The increasing tuberculosis (TB) disease prevalence is a major factor that is expected to drive growth of the global pyrazinamide market. For instance, according to the National Center for Biotechnology Information in 2019, total 8,920 number of TB disease new cases were provisionally reported in the U.S. according to same source, the rate of TB is around 2.7 per 100,000 persons. Moreover, TB is a major burden across the globe. According to TB Facts report organization data, in 2018, in the U.S, the cost of treating drug sensitive TB was US$ 49,000; treatment costs for MDR-TB averaged US$ 393,000; and treatment costs for XDR TB averaged US$ 758,000.
Global Pyrazinamide Market - Impact of Coronavirus (COVID-19) Pandemic
The spread of the novel coronavirus has hampered growth of the healthcare industry. In December 2019, a cluster of pneumonia cases were reported by Chinese health authorities in China’s Wuhan City. The pneumonia causative agent was identified as a novel coronavirus named COVID-19. This virus spread rapidly across the globe causing a concerning number of fatalities. In March, 2020, the World Health Organization (WHO) declared COVID-19 as a global pandemic and suggested implementation of strict measures to minimize the spread of this disease. The pandemic has slowed growth of the healthcare sector and led to a disturbance in the supply chain of pharmaceutical drugs.
Moreover, governments across various countries have implemented nationwide lockdowns to curb the spread of COVID-19. Similarly, in various countries across the world, healthcare companies are facing problems of continuing their supply chain operations. The slowdown of the supply chain has also impacted growth of the global pyrazinamide market.
The global pyrazinamide market is estimated to be valued at US$ 143.9 million in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027).
Fig. 1. Global Pyrazinamide Market Share (%) Analysis, By Patient Type, 2020
Global Pyrazinamide Market- Restraints
Increasing pyrazinamide drug resistant TB infection is a major factor that is expected to restrain growth of the global pyrazinamide market.
Pyrazinamide Market Report Coverage
||Market Size in 2020:
||US$ 143.9 Mn
|Historical Data for:
||2017 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 163.1 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Patient Type: Adult, Pediatric.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, City Chemical, EDQM, J & K SCIENTIFIC, Meryer (Shanghai) Chemical Technology, Energy Chemical, and Beijing Ouhe Technology.
- High burden of TB is driving growth of the market
|Restraints & Challenges:
- Increasing pyrazinamide drug resistant TB infection
Global Pyrazinamide Market: Regional Analysis
On the basis of region, the global pyrazinamide market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to witness significant growth in the global pyrazinamide market, owing to increasing number of TB patient across the U.S. and Canada respectively. For instance, in 2019, according to data of the Centers for Disease Control and Prevention states that, around 8,916 number of TB cases were reported in the U.S. Similarly, in 2017, according to the Canada government data, there were around 1,796 number of TB cases reported in Canada, when compared with around 1,750 number of TB cases in 2016, indicates a 2.6% increase.
Additionally, in Europe, growth of the pyrazinamide market is attributed to high number of TB patients. For instance, according to European Centre for Disease Prevention and Control data around 55,337 TB cases were reported in year 2017, which was around rate of 10.7 per 100,000 population.
Fig.2. Global Pyrazinamide Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
Global Pyrazinamide Market- Competitive Landscape
Key players operating in the global pyrazinamide market include Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, and, City Chemical.